<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03351868</url>
  </required_header>
  <id_info>
    <org_study_id>GIMI-IRB-17021</org_study_id>
    <nct_id>NCT03351868</nct_id>
  </id_info>
  <brief_title>FANCA Gene Transfer for Fanconi Anemia Using a High-safety, High-efficiency, Self-inactivating Lentiviral Vector</brief_title>
  <official_title>Gene Transfer for Fanconi Anemia Using a Self-inactivating Lentiviral Vector</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenzhen Geno-Immune Medical Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shenzhen Geno-Immune Medical Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I/II clinical trial of gene therapy for treating Fanconi anemia using a
      self-inactivating lentiviral vector to functionally correct the defective gene. The
      objectives are to evaluate the safety and efficacy of the gene transfer clinical protocol.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fanconi anemia is a rare, inherited disease that is caused by a gene defect and that
      primarily affects an individual's bone marrow, resulting in decreased production of blood
      cells. The major problem for most patients is aplastic anemia, the blood counts for red blood
      cells, white blood cells, and platelets are low. In addition, some patients have physical
      defects usually involving the skeleton and kidneys. Fanconi anemia is typically diagnosed in
      childhood, and there is a high fatality rate. Hematopoietic stem cell transplantation (HSCT)
      is a common treatment for Fanconi anemia. However, there are many risks associated with HSCT
      including rejection of the transplanted cells and graft-versus-host disease.

      The primary objectives are to evaluate the safety of the self-inactivating lentiviral vector,
      the ex vivo gene transfer clinical protocol and the efficacy of immune reconstitution in
      patients overcoming immune abnormalities present at the time of treatment, assessment of gene
      correction efficiency, and finally the long-term correction of Fanconi anemia associated
      disease symptoms.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety in patients using CTCAE version 4.0 standard to evaluate the level of adverse events</measure>
    <time_frame>6 months</time_frame>
    <description>Physiological parameter (measuring cytokine response, fever, symptoms)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment responses</measure>
    <time_frame>1 year</time_frame>
    <description>Blood routine indexes will be obtained before and after treatment. Objective response, such as complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD) will be assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>1 year</time_frame>
    <description>Quality of life will be measured using the Functional Assessment of Cancer Therapy-General (FACT-G) before and after treatment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Fanconi Anemia</condition>
  <arm_group>
    <arm_group_label>Gene-modified autologous stem cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous hematopoeitic stem cells and mesenchymal stem cells transduced with lentiviral vector carrying the FANCA gene ex vivo</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Gene-modified autologous stem cells</intervention_name>
    <description>Infusion for 5x10^6~1x10^7 per kilogram of body weight of gene-modified cells; or more infusions depending on the circumstances</description>
    <arm_group_label>Gene-modified autologous stem cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of Fanconi anemia FANCA type based on DNA sequencing and sensitivity test
             for chromosomal cleavage by mitomycin C or butylene oxide.

          2. No cytogenetic abnormalities and the proportion of myelodysplastic abnormalities does
             not exceed 5% within 3 months prior to stem cell collection.

          3. Age: ≥ 4 years.

          4. Karnofsky: ≥ 70%.

          5. ANC ≥ 5×10^8/L; PLT ≥ 2×10^10/L.

          6. Hemoglobin ≥ 8g/dL.

          7. Proper renal and hepatic functions (ULN denotes &quot;upper limit of normal range&quot;) with

               -  serum creatinine ≤ 1.5×ULN;

               -  serum bilirubin ≤ 3×ULN;

               -  AST/ALT ≤ 5×ULN.

          8. Pulmonary function is normal; DLCO &gt; 50%.

          9. Written, informed consent obtained prior to any study-specific procedures.

        Exclusion Criteria:

          1. Diagnosis of active malignant disease or myelodysplastic syndrome.

          2. Diagnosis of myeloid leukemia.

          3. Pregnant or lactating females.

          4. Existence of an available HLA-identical related donor.

          5. Subject infected with HBV (HBsAg positive), HIV (HIV antibody positive), HTLV (HTLV
             antibody positive), Treponema pallidum antibody positive or TB culture positive.

          6. Patients, in the opinion of investigators, may not be eligible or not able to comply
             with the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lung-Ji Chang, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shenzhen Geno-Immune Medical Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiao-Dong Shi, M.D./Ph. D</last_name>
    <role>Study Director</role>
    <affiliation>Capital Institute of Pediatrics affiliated Children's hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jie Zheng, M.D./Ph. D</last_name>
    <role>Study Director</role>
    <affiliation>Beijing Children's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lung-Ji Chang, Ph.D</last_name>
    <phone>86-13671121909</phone>
    <email>c@szgimi.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Capital Institute of Pediatrics affiliated Children's hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>XiaoDong Shi, M.D./P.H.D</last_name>
      <phone>+86-13911601076</phone>
      <email>xsusan28@sina.com</email>
    </contact>
    <contact_backup>
      <last_name>Lixiao Shi, M.M.</last_name>
      <phone>+86-18810963129</phone>
      <email>13780524314@163.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Beijing Children's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jie Zheng, MD/PhD</last_name>
      <phone>+86-13683284467</phone>
      <email>cutezjie@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shenzhen Geno-immune Medical Institute</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lung-Ji Chang, PhD</last_name>
      <phone>86-075586725195</phone>
      <email>c@szgimi.org</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2017</study_first_submitted>
  <study_first_submitted_qc>November 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2017</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shenzhen Geno-Immune Medical Institute</investigator_affiliation>
    <investigator_full_name>Lung-Ji Chang</investigator_full_name>
    <investigator_title>President</investigator_title>
  </responsible_party>
  <keyword>Fanconi anemia</keyword>
  <keyword>Lentiviral vector</keyword>
  <keyword>FANCA</keyword>
  <keyword>Gene</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Fanconi Anemia</mesh_term>
    <mesh_term>Fanconi Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

